Abstract: A child-resistant apparatus for dispensing articles which comprises a housing for retaining a blister package wherein the housing comprises a dispensing aperture; optionally, but preferably, a blister package comprising at least one blister cell containing an article to be dispensed; and a substantially rigid backing sheet substantially co-extensive with, and substantially blocking, the dispensing aperture, such that pressure exerted on an exposed top edge of the backing sheet imparts arcuate flexure thereto and dislocation thereof from the substantially co-extensive, and substantially blocking position, to a position where the dispensing aperture is unblocked permitting the at least one article contained in the at least one blister cell to be dispensed. Release of pressure on the exposed top edge of the backing sheet relaxes flexure thereof such that the substantially co-extensive, and substantially blocking position, wherein the backing sheet substantially blocks the dispensing aperture, is restored.
Abstract: This invention relates to novel processes for preparing the pharmaceutically active compound 5-(3-[(2S)-exo-bicyclo[2.2.1]hept-2-yloxy]-4-methoxyphenyl)-3,4,5,6-tetrahydropyrimidin-2(1H)-one and its corresponding 2R enantiomer and for preparing certain intermediates used in the synthesis of these compounds. It also relates to novel intermediates used in the synthesis of such pharmaceutically active compounds and to other novel compounds that are related to such intermediates.
Type:
Grant
Filed:
June 11, 2001
Date of Patent:
June 4, 2002
Assignee:
Pfizer INC
Inventors:
Thomas G. LaCour, Charles William Murtiashaw, III
Abstract: This invention relates to compounds of Formula I
or stereoisomers, pharmaceutically acceptable salts or prodrugs thereof or a pharmaceutically acceptable salts of the prodrugs. This invention also relates to pharmaceutical compositions comprising a compound of Formula I, and to methods of treatment of diabetes, insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis, or tissue ischemia.
Abstract: The present invention relates to novel DNA sequences that encode for the branched-chain alpha-ketoacid dehydrogenase complex of an organism belonging to the genus Streptomyces and to novel polypeptides produced by the expression of such sequences. It also relates to novel methods of enhancing the production of natural avermectin, of producing a Streptomyces avermitilis bkd mutant and of producing novel avermectins through fermentation.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
June 4, 2002
Assignee:
Pfizer Inc.
Inventors:
Claudio D. Denoya, Kim J. Stutzman-Engwall
Abstract: This invention provides an improved process for cis-1-{2-[4-(6-methoxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenoxy]ethyl}pyrrolidine which is an intermediate for the preparation of (−)cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydronaphthalene-2-ol which is useful for the treatment of osteoporosis.
Abstract: The present invention relates to heterocyclic ring-fused pyrimidine derivatives of formula (I) or stereoisomers, pharmaceutically acceptable salts or prodrugs thereof, wherein Z and Y are as defined in the specification.
Type:
Grant
Filed:
November 9, 1999
Date of Patent:
May 28, 2002
Assignee:
Pfizer Inc
Inventors:
Lee Daniel Arnold, Mikel P. Moyer, Susan B. Sobolov-Jaynes
Abstract: Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.
Type:
Grant
Filed:
September 27, 2000
Date of Patent:
May 28, 2002
Assignee:
Pfizer Inc.
Inventors:
Michael P. DeNinno, Christian J. Mularski, Roger B. Ruggeri, Ronald T. Wester
Abstract: The present invention relates to compositions and methods for treating the epithelial toxicity caused by administering to a human cancer patient an epidermal growth factor receptor (EGFR) inhibitor. The pharmaceutical composition preferably comprises an EGFR inhibitor and a keratinocyte growth factor (KGF) in a pharmaceutically-acceptable carrier. The method of treatment comprises co-administering to the patient a therapeutically effective amount of KGF with the EGFR inhibitor.
Type:
Application
Filed:
March 15, 2001
Publication date:
May 23, 2002
Applicant:
PFIZER PRODUCTS INC. & OSI PHARMACEUTICALS, INC.
Inventors:
Penelope Elizabeth Miller, James Dale Moyer
Abstract: Therapeutically active compositions of matter and member species thereof are described which comprise indazole-containing compounds, said compounds and their therapeutic activity resulting directly from an indazole-for-catechol bioisostere replacement of a catechol-containing compound having the same therapeutic activity, where non-catechol substituents are the same or homologous before and after said replacement, and wherein said compositions of matter comprise a compound of Formula (I1) or (I2):
or a pharmaceutically acceptable salt thereof, wherein in a preferred embodiment RC is hydrogen; RA is cyclohexyl; and RB is ethyl.
Abstract: This invention provides terpenoid lactone compounds, and processes for producing the terpenoid lactone compounds, which comprise cultivating Oidiodedron griseum FERM BP-5778 and then isolating the terpenoid lactone compounds from the fermentation broth. The present invention also provides a pharmaceutical composition comprising the terpenoid lactone compound, which is useful in the treatment of IL-1 and TNF mediated diseases or the like.
Abstract: The present invention provides an homogenate prepared from cells of Neospora, and vaccines against neosporosis prepared therefrom which are useful in the prevention of clinical disease and abortion in mammals.
Abstract: The present invention relates to compounds of formula 1
and pharmaceutically acceptable salts and solvates thereof wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and Z are as defined herein. The invention also relates to pharmaceutical compositions comprising compounds of formula 1 and to methods of inhibiting abnormal cell growth, including cancer, in a mammal by administering compounds of formula 1 to the mammal. The invention also relates to intermediates and methods useful in synthesizing compounds of formula 1.
Abstract: A method for treating glaucoma and ischemic retinopathy in a mammal, comprising administering to said mammal a therapeutically effective amount of a compound of the formula
or a pharmaceutically acceptable acid addition salt thereof, wherein n, X, Y and Ar are as defined in the specification.
Abstract: Two crystalline polymorphic forms of (2-Benzhydryl-1-azo-bicyclo[2.2.2]oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-amine citrate monohydrate (the monohydrates) are Form A and Form B. The pharmaceutical composition containing at least one of these polymorphs has advantageous stability for formulation to treat acute emesis in patient receiving chemotherapy. The administration of this pharmaceutical composition is conventional oral by preferably tablet or capsule and intravenous. A method of making A and B Forms is also disclosed.
Type:
Grant
Filed:
May 12, 2000
Date of Patent:
May 14, 2002
Assignee:
Pfizer Inc.
Inventors:
George Joseph Quallich, Lewin Theophilus Wint, Peter Robert Rose, Stephen S. Massett
Abstract: Isoxazole-sulfonamide endothelin antagonists of formula (I) below having good affinity for endothelin receptors and selectivity for ETA over ETB are described herein.
Such compounds are useful in the treatment of conditions mediated by endothelin, in particular, conditions mediated by endothelin ETA.
Type:
Grant
Filed:
May 30, 2001
Date of Patent:
May 14, 2002
Assignee:
Pfizer Inc.
Inventors:
Bernard Joseph Banks, Nathan Anthony Logan Chubb, James John Eshelby, Michael Stephen Pacey, Darren John Schulz
Abstract: The present invention relates to compositions and methods of achieving a therapeutic effect including, but not limited to, the treatment of congestive heart failure or hypertension in an animal, preferably a mammal including a human subject or a companion animal, using a corticotropin releasing factor (CRF) antagonist and a renin-angiotensin system (RAS) inhibitor.
Abstract: The present invention relates to a process for preparing a compound of the formula
wherein b, Y and R3 are defined as above, useful for preparing novel aralkyl and aralkylidene heterocyclic lactams and imides which are selective agonists and antagonists of serotonin 1 (5-HT1) receptors.
Type:
Grant
Filed:
March 28, 2000
Date of Patent:
May 14, 2002
Assignee:
Pfizer INC
Inventors:
George Joseph Quallich, Jeffrey William Raggon, Paul D. Hill
Abstract: Compounds of formula (I):
or pharmaceutically or veterinarily acceptable salts thereof, or pharmaceutically or veterinarily acceptable solvates of either entity, wherein the broken line represents an optional bond; A is C or CH; B is CH2, O or absent; R1 and R2 are each independently selected from hydrogen, C1 to C6 alkyl optionally substituted with C1 to C4 alkoxy or phenyl, and C1 to C6 alkenyl; or, together with the carbon atom to which they are attached, form a C3 to C6 cycloalkyl group which optionally incorporates a heteroatom linkage selected from O, SO, SO2 and NR6 or which is optionally benzo-fused; R3 is hydrogen, halo, R7 or OR7; R4 is hydrogen, C1 to C4 alkyl, C1 to C4 alkoxy, trifluoromethyl or halo; R6 is hydrogen or C1 to C4 alkyl; R7 is an optionally substituted monocyclic or bicyclic ring system; m is 1 or 2; and n is 0, 1 or 2; with the proviso that B is not O when A is C; are MMP inhibitors useful in the treatment of, inter alia, tissue ulceration, wound repair and skin di
Type:
Grant
Filed:
October 12, 2001
Date of Patent:
May 14, 2002
Assignee:
Pfizer INC
Inventors:
Kevin Neil Dack, Gavin Alistair Whitlock